EAM
Exome Asset Management Portfolio holdings
AUM
$110M
This Quarter Return
+9.77%
1 Year Return
+24.83%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$133M
AUM Growth
+$133M
(-10%)
Cap. Flow
-$15.9M
Cap. Flow
% of AUM
-11.94%
Top 10 Holdings %
Top 10 Hldgs %
37.04%
Holding
83
New
23
Increased
12
Reduced
17
Closed
24
Top Buys
| 1 |
Humana
HUM
|
$4.58M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
$4.22M |
| 3 |
Arvinas
ARVN
|
$4.19M |
| 4 |
Boston Scientific
BSX
|
$3.62M |
| 5 |
Soleno Therapeutics
SLNO
|
$3.47M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$6.55M |
| 2 |
TG Therapeutics
TGTX
|
$4.86M |
| 3 |
Align Technology
ALGN
|
$4.76M |
| 4 |
Cigna
CI
|
$4.23M |
| 5 |
BioNTech
BNTX
|
$4.1M |
Sector Composition
| 1 | Healthcare | 98.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Savara
SVRA
$591M
| $2.15M | 1.61% |
+699,698
| New | +$2.15M |
|
27
Ionis Pharmaceuticals
IONS
$9.64B
| $2.15M | 1.61% |
+61,367
| New | +$2.15M |
|
28
Penumbra
PEN
$10.5B
| $2.14M | 1.61% |
+9,000
| New | +$2.14M |
|
29
Rocket Pharmaceuticals
RCKT
$358M
| $2.01M | 1.51% |
+159,552
| New | +$2.01M |
|
30
Akero Therapeutics
AKRO
$3.65B
| $1.91M | 1.43% |
68,608
-8,492
| -11% | -$236K |
|
31
Dr. Reddy's Laboratories
RDY
$11.8B
| $1.86M | 1.39% |
117,500
+81,200
| +224% | -$1.01M |
|
|
ONC
32
BeOne Medicines Ltd. American Depositary Shares
ONC
$37B
| $1.85M | 1.39% |
10,000
-5,300
| -35% | -$979K |
|
33
89bio
ETNB
$1.37B
| $1.76M | 1.32% |
225,323
-75,277
| -25% | -$589K |
|
34
Tarsus Pharmaceuticals
TARS
$2.44B
| $1.56M | 1.17% |
28,178
-17,422
| -38% | -$965K |
|
35
Pliant Therapeutics
PLRX
$105M
| $1.36M | 1.02% |
103,504
-46,096
| -31% | -$607K |
|
36
Fulcrum Therapeutics
FULC
$353M
| $1.33M | 1% |
+283,599
| New | +$1.33M |
|
37
Stoke Therapeutics
STOK
$1.08B
| $1.25M | 0.94% |
113,096
-63,504
| -36% | -$700K |
|
38
Legend Biotech
LEGN
$6.64B
| $1.22M | 0.92% |
37,600
-9,400
| -20% | -$306K |
|
|
TECX
39
Tectonic Therapeutic, Inc. Common Stock
TECX
$305M
| $1.2M | 0.9% |
26,081
-10,263
| -28% | -$474K |
|
40
Alvotech
ALVO
$2.48B
| $1.19M | 0.9% |
90,100
| – | – |
|
41
VYNE Therapeutics
VYNE
$8.09M
| $1.18M | 0.89% |
353,434
| – | – |
|
42
Eledon Pharmaceuticals
ELDN
$155M
| $1.06M | 0.79% |
+256,373
| New | +$1.06M |
|
43
Biohaven
BHVN
$1.71B
| $1.05M | 0.79% |
+28,159
| New | +$1.05M |
|
44
Gossamer Bio
GOSS
$587M
| $993K | 0.75% |
1,097,999
+629,500
| +134% | +$569K |
|
45
Aclaris Therapeutics
ACRS
$223M
| $966K | 0.73% |
+389,333
| New | +$966K |
|
46
Annexon
ANNX
$225M
| $743K | 0.56% |
+144,830
| New | +$743K |
|
47
Veru
VERU
$48.5M
| $740K | 0.56% |
+1,117,600
| New | +$740K |
|
|
SLRN
48
DELISTED
ACELYRIN
SLRN
| $736K | 0.55% |
+234,435
| New | +$736K |
|
49
Replimune Group
REPL
$460M
| $663K | 0.5% |
+54,738
| New | +$663K |
|
50
Establishment Labs
ESTA
$1.11B
| $604K | 0.45% |
13,100
-8,600
| -40% | -$396K |
|